In recent years faecal blood loss due to ingestion of acetyl salicylic acid (ASA) has been demonstrated by various authors, both by chemical methods such as the benzidine reaction, and by physical methods with erythrocytes labelled with radioactive substances. Stubbe (1958) reported occult faecal blood loss in 70 per cent. and Alvarez and Summerskill (1958) in 50 per cent. of patients and healthy volunteers taking ASA. Scott, Porter, Lewis, and Dixon (1961) , reporting a 70 per cent. incidence of faecal blood loss with ASA, found no indication as to the actual site of bleeding and no correlation between dyspepsia and blood loss. Stubbe (1958) time and again found normal values for the bleeding time and assumed a local irritant action of ASA on the gastric mucosa to be responsible for the faecal blood loss. Entericcoated ASA tablets, at least those commercially available, provide "no protection of the gastric mucosa" as faecal blood loss was reported in about 32 per cent. of cases by Scott and others (1961) and in 65 per cent. of cases by Stubbe (1958) and also by Lange (1957) . Also Pierson, Holt, Watson, and Keating (1961) found that enteric-coated ASA induced the same rate of bleeding as non-coated ASA; according to these authors the intestinal mucosa is also susceptible to ASA irritation. With a special experimental coating of ASA tablets, faecal blood loss was reduced to a minimum (Stubb6, Pietersen, and van Heulen, 1962) .
In addition to the 50 to 70 per cent incidence of faecal blood loss presumably due to gastric irritation, there are incidental reports of manifest bleeding during medication with ASA after tooth-extraction (Smith and MacKinnon, 1951) , post-biopsy bleeding and epistaxis (Frick, 1956) , haematuria, bleeding gums, menorrhagia (Wising, 1952) , and after tonsillectomy (Neivert, 1945) . Here, factors other than 50 gastric irritation must be present.
On account of the unknown pathogenesis of ASAinduced occult faecal blood, and of the reports of frank bleeding following the ingestion of ASA, a study was made of the influence of ASA on haemostasis.
Methods and Material
In this study ASA was given in a daily dosage of 3 g., two tablets of 0 5 g. dissolved in water three times a day after meals. Six healthy adults (three males and three females) and eight adult female patients with definite rheumatoid arthritis (A.R.A. criteria) were examined. Patients taking corticosteroids, Butazolidin, anticoagulants, or recent salicylate medication were excluded. With other medications such as gold salts or antimalarials, care was taken that the dosage had not been changed in the 2 months before the experiment. The following haemostatic parameters were studied before ASA ingestion and during the second week of ASA ingestion.
Vascular Factors andPlatelets
Capillary fragility ( (Tables III and IV, below), in which the author was unaware of the medication given.
All the tests were performed by the author. These data were analysed by the Wilcoxon two-sample test. Finally, the bleeding time tests were performed by a technician, in a double-blind situation, on seven patients, with definite rheumatoid arthritis, again before and during acetyl salicylic acid ingestion (Table V, below) .
Results
The haemostatic mechanism in the eight patients with rheumatoid arthritis was essentially the same as in the six healthy adults. Of the eight patients with rheumatoid arthritis, five showed an increased plasma-fibrinogen concentration, and subsequently an increased maximal amplitude on the thrombelastogram. The other haemostatic parameters, however, were normal.
Hence it was justifiable to analyse the changes induced by ASA in these two groups together. Only those haemostatic parameters which showed a statistically significant difference at a 0 05 level with the Wilcoxon test for symmetry, are listed in Table  I , with their P values, and their mean value before and during ASA ingestion. Thus no significant changes occured in the platelet count, the capillary fragility, clot retraction, thromboplastin generation, or Factor II, V, VII, or X activity. Haematuria remained absent.
The difference in bleeding time between the patients that were off and those that were on ASA is highly significant by the Wilcoxon two-sample test: P = 0 00007 for the first group of 31 patients (Table II) . In the blind situation the P value remains significant, P = 0 0008 in 1958 (Table III) and P = 0 006 in 1961 (Table IV) . These three groups together contain 86 patients, 57 off ASA and 29 taking ASA 3 g. daily. The difference in bleeding time between these patients is highly significant (P = 2 x 10-8).
The bleeding times estimated by a technician in a double-blind situation on seven patients before and during ASA show prolongation in all cases (P = 0 * 008) ( Table V) . Signs of manifest bleeding in the patients taking ASA did not occur during this study.
Discussion
ASA prolonged the prothrombin time from 13-7 to 14 -1 sec., which proved to be statistically significant. Clinically, however, this small prolongation is of no importance whatsoever. Link, Overman, Sullivan, Huebner, and Scheel (1943) , Shapiro, Redish, and Campbell (1943) , Meyer and Howard (1943) , and Quick and Clesceri (1960) have all described a slight to moderate fall in prothrombin concentration, hence a prolongation of prothrombin time on a relatively large dose of 5 -3 to 8 g. ASA daily. A marked fall in prothrombin concentration is seen only when massive doses of ASA are given, and even then the level is seldom low enough to cause haemorrhage (Butt, Leake, Solley, Griffith, Huntingdon, and Montgomery, 1945) .
There is a weak indication (P = 0 049) that the packed cell volume decreases during ASA ingestion, which agrees with citations in Goodman and Gilman (1955 The bleeding time in the six healthy adults and eight patients with rheumatoid arthritis studied initially, increased in all cases, from a mean of 161 sec. before ASA to 302 sec. in the 2nd week of ASA ingestion. Although this change proved to be. strongly significant (P = 3 10-5), the very nature of the bleeding time determination calls for further discussion. According to Ivy, Shapiro, and Melnick (1935) and Ivy and others (1941) , the upper limit of normal bleeding is 240 sec., but in their 1 15 healthy volunteers, the bleeding time rarely exceeded 180 sec. In setting a "clinically normal" maximum bleeding time at 240 sec., patients with mild bleeding tendency may be diagnosed as normal. Biggs and MacFarlane (1962) , using Ivy's technique, found a normal bleeding time to be from 21 to 7 minutes. Without ASA medication, the author found a mean bleeding time in 81 tests in adults of 137 sec., standard deviation of 45* 5. Normal bleeding time estimated by a technician in the same laboratory using an identical technique is 92 sec. (range 68 to 141). The difference in "normal values" for the Ivy bleeding time found by various investigators using identical techniques is due to differences in the pressure applied on the blade and in determining the end-point of bleeding. It is difficult to determine when bleeding has stopped and when a small amount of red-tinted serum starts being expressed from the clotted blood. It is at this end-point of bleeding, that unconscious bias can easily occur. Hence it was imperative to perform the bleeding time test in a "double-blind situation". In the two groups examined by the author in a double-blind situation (Tables III and IV) , the differences with and without ASA remained statistically significant, and the bleeding time estimated by a technician in a doubleblind situation on seven patients before and during ASA medication also showed a statistically significant prolongation (Table V) . The statistical analysis of the data was performed with the Wilcoxon two-sample test, rather than with means and standard deviations. For clinical purposes the normal bleeding time was 137-3 sec. ± S.D. 45-5 in 81 tests. During the ingestion of 3 g. ASA daily, the bleeding time measured 255 *4 sec. ± S.D. 76 1 in 64 tests. Beaumont and Willie (1955) and Beaumont, Willie, and Lenegre (1955) (Beaumont, Caen, and Bernard, 1956) , the bleeding time increased from 2 75 to 4 06 minutes on the third day of ASA ingestion. In children with haematological disorders such as leukaemia and haemophilia, ASA caused further prolongation in the already prolonged bleeding time. Very interesting is the observation of Beaumont and others (1956) that, in three children with platelet disorders and prolonged bleeding time aspirin did not induce further prolongation. This supports the conclusions of Bounameaux and van Cauwenberge (1954) , who demonstrated that sodium salicylate decreased platelet stickiness in rats. In Beaumont's three cases poor platelet function presumably could not be further reduced by aspirin. Hofmann (1956) induced progressive prolongation of bleeding time in mice, correlating closely with increasing doses of ASA or sodium salicylate. Blatrix (1963) also demonstrated a prolongation of the bleeding time and an increase in the volume of blood loss with ASA doses in excess of 40 mg./kg. bodyweight daily. Quick and Clesceri (1960) found no prolongation of the bleeding time (Duke's technique) in ten normal adults on 6 g. ASA daily, but the results on the one subject, reported as representative for his group of ten, do show an increase in bleeding time from 1H to 3 minutes.
In general the bleeding time in patients on ASA is in the range encountered in mild haemorrhagic diathesis. The changes in haemostasis induced by ASA are definitely not sufficient to cause major haemorrhage, and if this occurs individual susceptibility to ASA must be assumed (Frick, 1956 ). On the other hand, haemostasis is impaired and this should be reckoned with, as menorrhagia or bleeding following tooth-extraction or tonsillectomy may occur. Performing a closed hepatic biopsy during ASA ingestion is thus contraindicated. ASA increased the incidence of late haemorrhage following tonsillectomy from 0 1 to 8 7 per cent. (Fox and West, 1947) .
This study does not clarify the pathogenesis of ASA-induced faecal blood loss. However, from incidental observation, we are inclined to conclude that a mild haemorrhagic diathesis may cause faecal blood loss, e.g. in low-grade haemophilia, low-grade thrombocytopenia, and von Willebrand's disease. No reports on the incidence of faecal blood loss in these diseases are available. During anticoagulant therapy (also a mild haemorrhagic diathesis) an increase from the "normal faecal blood loss of 0 5 to 1 * ml. daily" was demonstrated by Watson and Pierson (1961) . The possibility remains that the ASA-induced faecal blood loss is caused not only by gastric or intestinal mucosal irritation, but also by the concomitant mild haemorrhagic state. This would help to explain the 70 per cent. incidence of faecal blood loss while gastroscopic studies revealed gastric mucosal bleeding due to a direct irritation by ASA in only 20 per cent. of cases (Weiss, Pitman, and Graham, 1961) . Entericcoated aspirin tablets, which presumably do not irritate the gastric mucosa, may still induce a mild haemorrhagic diathesis with subsequent increased faecal blood loss. Summary Aspirin in a dose of 3 g. daily by mouth induced definite prolongation of the bleeding time and a decrease in platelet-stickiness in six healthy adults and eight patients with rheumatoid arthritis. The prolongation of the bleeding time was confirmed in a larger sample in a double-blind situation. The implications are discussed. hkmostatiques RESUME L'aspirine a la dose de 3 g. par jour par voie buccale induisait une prolongation definie du temps de saignement et une diminution de la viscosite thrombocytaire chez six adultes sains et huit malades atteints d'arthrite rhumatismale. La prolongation du temps de saignement fut confirmee sur une plus grande echelle et dans une situation qui ressemblait un essai par la methode de double-blind. On en discute les implications.
La influencia de la aspirina sobre los parametros hemostiticos SUMARIO La aspirina a la dosis de 3 g. diarios por via oral producia una prolongaci6n definida del tiempo de sangria y una diminuci6n de la viscosidad trombocitaria en seis adultos sanos y ocho enfermos con artritis reumatoide. La prolongaci6n del tiempo de sangria fue confirmada en un mayor nuimero de casos y en una situacion de ensayo por el metodo de double-blind. Se discuten las implicaciones de esta investigaci6n.
